You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 19, 2024

Claims for Patent: 5,210,079


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 5,210,079
Title: Treatment of chronic renal failure with imidazole angiotensin-II receptor antagonists
Abstract:Substituted imidazoles such as 2-butyl-4-chloro-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]-5-(hydroxy methyl)imidazole and 2-butyl-4-chloro-1-[(2'-carboxybiphenyl-4-yl)-methyl]-5-(hydroxymethyl)imi dazole and pharmaceutically acceptable salts thereof are useful for treating chronic renal failure, mediated by angiotensin-II.
Inventor(s): Carini; David J. (Wilmington, DE), Duncia; John Jonas V. (Newark, DE), Wong; Pancras C. (Wilmington, DE)
Assignee: E. I. Du Pont de Nemours and Company (Wilmington, DE)
Application Number:07/832,638
Patent Claims: 1. A method of treating chronic renal failure mediated by AII in a mammal comprising administering to the mammal a therapeutically effective amount of a pharmaceutical composition having the formula (I): ##STR37## wherein R.sup.1 is 4--CO.sub.2 H; 4--CO.sub.2 R.sup.9 ; ##STR38## R.sup.2 is H; Cl; Br; I; F; NO.sub.2 ; CN; alkyl of 1 to 4 carbon atoms; acyloxy of 1 to 4 carbon atoms; alkoxy of 1 to 4 carbon atoms; CO.sub.2 H; CO.sub.2 R.sup.9 ; NHSO.sub.2 CH.sub.3 ; NHSO.sub.2 CF.sub.3 ; CONHOR.sup.12 ; SO.sub.2 NH.sub.2 ; ##STR39## aryl; or furyl; R.sup.3 is H; Cl, Br, I or F; alkyl of 1 to 4 carbon atoms or alkoxy of 1 to 4 carbon atoms;

R.sup.4 is CN, NO.sub.2 or CO.sub.2 R.sup.11 ;

R.sup.5 is H, alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms, alkenyl or alkynyl of 2 to 4 carbon atoms;

R.sup.6 is alkyl of 2 to 10 carbon atoms, alkenyl or alkynyl of 3 to 10 carbon atoms or the same groups substituted with F or CO.sub.2 R.sup.14 ; cycloalkyl of 3 to 8 carbon atoms, cycloalkylalkyl of 4 to 10 carbon atoms; cycloalkylalkenyl or cycloalkylalkynyl of 5 to 10 carbon atoms; (CH.sub.2).sub.s Z(CH.sub.2).sub.m R.sup.5 optionally substituted with F or CO.sub.2 R.sup.14 ; benzyl or benzyl substituted on the phenyl ring with 2 or 2 halogens, alkoxy of 1 to 4 carbon atoms, alkyl of 1 to 4 carbon atoms or nitro;

R.sup.7 is H, F, Cl, Br, I, NO.sub.2, C.sub.v F.sub.2v+1, where v=1-6; C.sub.6 F.sub.5 ; CN; ##STR40## straight or branched alkyl of 1 to 6 carbon atoms; phenyl or phenylalkyl, where alkyl is 1 to 3 carbon atoms; or substituted phenyl or substituted phenylalkyl, where alkyl is 1 to 3 carbon atoms, substituted with one or two substituents selected from alkyl of 1 to 4 carbon atoms, F, Cl, Br, OH, OCH.sub.3, CF.sub.3, and COOR, and R is H, alkyl of 1 to 4 carbon atoms, or phenyl;

R.sup.8 is H, CN, alkyl of 1 to 10 carbon atoms, alkenyl of 3 to 10 carbon atoms, or the same groups substituted with F; phenylalkenyl wherein the alkenyl portion is 2 to 6 carbon atoms; --(CH.sub.2).sub.m -imidazol-1-yl; --(CH.sub.2).sub.m -1,2,3-triazolyl optionally substituted with one or two groups selected from CO.sub.2 CH.sub.3 or alkyl of 1 to 4 carbon atoms; --(CH.sub.2).sub.s -tetrazolyl; ##STR41## R.sup.9 is ##STR42## R.sup.10 is alkyl of 1 to 6 carbon atoms or perfluoroalkyl of 1 to 6 carbon atoms, 1-adamantyl, 1-naphthyl, 1-(1-naphthyl)ethyl, or (CH.sub.2).sub.p C.sub.6 H.sub.5 ;

R.sup.11 is H, alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms, phenyl or benzyl;

R.sup.12 is H, methyl or benzyl;

R.sup.13 is --CO.sub.2 H; --CO.sub.2 R.sup.9 ; --CH.sub.2 CO.sub.2 H, --CH.sub.2 CO.sub.2 R.sup.9 ; ##STR43## R.sup.14 is H, alkyl or perfluoroalkyl of 1 to 8 carbon atoms, cycloalkyl of 3 to 6 carbon atoms, phenyl or benzyl;

R.sup.15 is H, alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms, phenyl, benzyl, acyl of 1 to 4 carbon atoms, phenacyl;

R.sup.16 is H, alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms, (CH.sub.2).sub.p C.sub.6 H.sub.5, OR.sup.17, or NR.sup.18 R.sup.19 ;

R.sup.17 is H, alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms, phenyl or benzyl;

R.sup.18 and R.sup.19 independently are H, alkyl of 1 to 4 carbon atoms, phenyl, benzyl, .alpha.-methylbenzyl, or taken together with the nitrogen form a ring of the formula ##STR44## Q is NR.sup.20, O or CH.sub.2 ; R.sup.20 is H, alkyl of 1-4 carbon atoms, or phenyl;

R.sup.21 is alkyl of 1 to 6 carbon atoms, --NR.sup.22 R.sup.23, or ##STR45## R.sup.22 and R.sup.23 independently are H, alkyl of 1 to 6 carbon atoms, benzyl, or are taken together as (CH.sub.2).sub.u where u is 3-6;

R.sup.24 is H, CH.sub.3 or --C.sub.6 H.sub.5 ;

R.sup.25 is NR.sup.27 R.sup.28, OR.sup.28, NHCONH.sub.2, NHCSNH.sub.2, ##STR46## R.sup.26 is hydrogen, alkyl with from 1 to 6 carbon atoms, benzyl, or allyl;

R.sup.27 and R.sup.28 are independently hydrogen, alkyl with from 1 to 5 carbon atoms, or phenyl;

R.sup.29 and R.sup.30 are independently alkyl of 1-4 carbon atoms or taken together are --(CH.sub.2).sub.q --;

R.sup.31 is H, alkyl of 1 to 4 carbon atoms, --CH.sub.2 CH.dbd.CH.sub.2 or --CH.sub.2 C.sub.6 H.sub.4 R.sup.32 ;

R.sup.32 is H, NO.sub.2, NH.sub.2, OH or OCH.sub.3 ;

X is a carbon-carbon single bond, --CO--, --CH.sub.2 --, --O--, --S--, --NH--, ##STR47## --OCH.sub.2 --, --CH.sub.2 O--, --SCH.sub.2 --, --CH.sub.2 S--, --NHC(R.sup.27)(R.sup.28)--, --NR.sup.23 SO.sub.2 --, --SO.sub.2 NR.sup.23 --, --C(R.sup.27)(R.sup.28)NH--, --CH.dbd.CH--, --CF.dbd.CF--, --CH.dbd.CF--, --CF.dbd.CH--, --CH.sub.2 CH.sub.2 --, --CF.sub.2 CF.sub.2 --, ##STR48## Y is O or S; Z is O, NR.sup.11, or S;

m is 1 to 5;

n is 1 to 10;

p is 0 to 3;

q is 2 to 3;

r is 0 to 2;

s is 0 to 5;

t is 0 or 1;

and pharmaceutically acceptable salt of these compounds; provided that:

(1) the R.sup.1 group is not in the ortho position;

(2) when R.sup.1 is ##STR49## X is a single bond, and R.sup.13 is CO.sub.2 H, or ##STR50## then R.sup.13 must be in the ortho or meta position; or when R.sup.1 and X are as above and R.sup.13 is NHSO.sub.2 CF.sub.3 or NHSO.sub.2 CH.sub.3, R.sup.13 must be ortho;

(3) when R.sup.1 is ##STR51## and X is other than a single bond, then R.sup.13 must be ortho except when X=NR.sup.23 CO and R.sup.13 is NHSO.sub.2 CF.sub.3 or NHSO.sub.2 CH.sub.3, then R.sup.13 must be ortho or meta;

(4) when R.sup.1 is 4--CO.sub.2 H or a salt thereof, R.sup.6 cannot be S-alkyl;

(5) when R.sup.1 is 4--CO.sub.2 H or a salt thereof, the substituent on the 4-position of the imidazole cannot be CH.sub.2 OH, CH.sub.2 OCOCH.sub.3, or CH.sub.2 CO.sub.2 H;

(6) when R.sup.1 is ##STR52## X is --OCH.sub.2 --, and R.sup.13 is 2--CO.sub.2 H, and R.sup.7 is H then R.sup.6 is not C.sub.2 H.sub.5 S;

(7) when R.sup.1 is ##STR53## and R.sup.6 is n-hexyl, then R.sup.7 and R.sup.8 are not both hydrogen; (8) when R.sup.1 is ##STR54## R.sup.6 is not methoxybenzyl; (9) the R.sup.6 group is not --CHFCH.sub.2 CH.sub.2 CH.sub.3 or CH.sub.2 OH;

(10) when r=O, R.sup.1 is ##STR55## X is --NH--CO--, R.sup.13 is 2--NHSO.sub.2 CF.sub.3, and R.sup.6 is n-propyl, then R.sup.7 and R.sup.8 are not --CO.sub.2 CH.sub.3 ;

(11) when r=0, R.sup.1 is ##STR56## X is --NH--CO--, R.sup.13 is 2--COOH, and R.sup.6 is n-propyl, then R.sup.7 and R.sup.8 are not --CO.sub.2 CH.sub.3 ;

(12) when r=1, R.sup.1 = ##STR57## X is a single bond, R.sup.7 is Cl, and R.sup.8 is --CHO, then R.sup.13 is not 3-(tetrazol-5-yl);

(13) when r=1, R.sup.1 = ##STR58## X is a single bond, R.sup.7 is Cl, and R.sup.8 is --CHO, then R.sup.13 is not 4-(tetrazol-5-yl).

2. Method of claim 1 wherein, in the compound of formula I is a compound of formula II: ##STR59## wherein R.sup.1 is --CO.sub.2 H; --NHSO.sub.2 CF.sub.3 ; ##STR60## R.sup.6 is alkyl of 3 to 10 carbon atoms, alkenyl of 3 to 10 carbon atoms, alkynyl of 3 to 10 carbon atoms, cycloalkyl of 3 to 8 carbon atoms, benzyl substituted on the phenyl ring with up to two groups selected from alkoxy of 1 to 4 carbon atoms, halogen, alkyl of 1 to 4 carbon atoms, and nitro;

R.sup.8 is ##STR61## phenylalkenyl wherein the alkenyl portion is 2 to 4 carbon atoms; --(CH.sub.2).sub.m -imidazol-1-yl; or --(CH.sub.2).sub.m -1,2,3-triazolyl optionally substituted with one or two groups selected from --CO.sub.2 CH.sub.3 or alkyl of 1 to 4 carbon atoms;

R.sup.13 is --CO.sub.2 H, --CO.sub.2 R.sup.9, NHSO.sub.2 CF.sub.3 ; SO.sub.3 H; or ##STR62## R.sup.16 is H, alkyl of 1 to 5 carbon atoms, OR.sup.17, or NR.sup.18 R.sup.19 ; X is carbon-carbon single bond, --CO--, --CH.sub.2 CH.sub.2 --, ##STR63## --OCH.sub.2 --, --CH.sub.2 O--, --O--, --SCH.sub.2 --, --CH.sub.2 S--, --NH--CH.sub.2 --, --CH.sub.2 NH-- or --CH.dbd.CH--; or a pharmaceutically acceptable salt thereof.

3. Method of claim 2 wherein the compound of formula II is a compound wherein:

R.sup.2 is H, alkyl of 1 to 4 carbon atoms, halogen, or alkoxy of 1 to 4 carbon atoms;

R.sup.6 is alkyl, alkenyl or alkynyl of 3 to 7 carbon atoms;

R.sup.7 is H, Cl, Br, I; C.sub.v F.sub.2v+1, where v=1-3; ##STR64## straight or branched chain alkyl of 1 to 6 carbon atoms; or phenyl; R.sup.8 is ##STR65## R.sup.10 is CF.sub.3, alkyl of 1 to 6 carbon atoms or phenyl; R.sup.11 is H, or alkyl of 1 to 4 carbon atoms;

R.sup.13 is CO.sub.2 H; CO.sub.2 CH.sub.2 OCOC(CH.sub.3).sub.3 ; NHSO.sub.2 CF.sub.3 ; ##STR66## R.sup.14 is H, or alkyl of 1 to 4 carbon atoms; R.sup.15 is H, alkyl of 1 to 4 carbon atoms, or acyl of 1 to 4 carbon atoms;

R.sup.16 is H, alkyl of 1 to 5 carbon atoms; OR.sup.17 ; or ##STR67## m is 1 to 5; X=single bond, --O--; --CO--; --NHCO--; or --OCH.sub.2 --; or

a pharmaceutically acceptable salt thereof.

4. Method of claim 3 wherein the compound of formula II is a compound wherein R.sup.1 is ##STR68## and X is a single bond; or a pharmaceutically suitable salt thereof.

5. Method of claim 4 wherein the compound of formula II is 2-Butyl-4-chloro-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]-5-(hydroxy methyl)imidazole or a pharmaceutically acceptable salt thereof.

6. Method of claim 4 wherein the compound of formula II is 2-Butyl-4-chloro-1-[(2'-carboxybiphenyl-4-yl)methyl]-5-(hydroxymethyl)imid azole or a pharmaceutically acceptable salt thereof.

7. Method of claim 4 wherein the compound of formula II is 2-Butyl-4-chloro-1-[(2'-carboxybiphenyl-4-yl)methyl]-5-[(methoxycarbonyl)a minomethyl]imidazole or a pharmaceutically acceptable salt thereof.

8. Method of claim 4 wherein the compound of formula II is 2-Butyl-4-chloro-1-[(2'-carboxybiphenyl-4-yl)methyl]-5-[(propoxycarbonyl)a minomethyl]imidazole or a pharmaceutically acceptable salt thereof.

9. Method of claim 4 wherein the compound of formula II is 2-Butyl-4-chloro-1-[(2'-carboxybiphenyl-4-yl)methyl]imidazole-5-carboxalde hyde or a pharmaceutically acceptable salt thereof.

10. Method of claim 4 wherein the compound of formula II is 2-Butyl-1-[(2'-carboxybiphenyl-4-yl)methyl]-imidazole-5-carboxaldehyde or a pharmaceutically acceptable salt thereof.

11. Method of claim 4 wherein the compound of formula II is 2-(1E-Butenyl)-4-chloro-1-[(2'-carboxybiphenyl-4-yl)methyl]-5-(hydroxymeth yl)imidazole or a pharmaceutically acceptable salt thereof.

12. Method of claim 4 wherein the compound of formula II is 2-(1E-Butenyl)-4-chloro-1-[(2'-carboxybiphenyl-4-yl)methyl]imidazole-5-car boxaldehyde or a pharmaceutically acceptable salt thereof.

13. Method of claim 4 wherein the compound of formula II is 2-Propyl-4-chloro-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]-5-(hydrox ymethyl) imidazole or a pharmaceutically acceptable salt thereof.

14. Method of claim 4 wherein the compound of formula II is 2-Propyl-4-chloro-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole- 5-carboxaldehyde or a pharmaceutically acceptable salt thereof.

15. Method of claim 4 wherein the compound of formula II is 2-Butyl-4-chloro-1-[2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole-5- carboxaldehyde or a pharmaceutically acceptable salt thereof.

16. Method of claim 4 wherein the compound of formula II is 2-(1E-Butenyl)-4-chloro-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]-5-h ydroxymethyl)imidazole or a pharmaceutically acceptable salt thereof.

17. Method of claim 4 wherein the compound of formula II is 2-(1E-Butenyl)-4-chloro-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imid azole-5-carboxaldehyde or a pharmaceutically acceptable salt thereof.

18. Method of claim 4 wherein the compound of formula II is 2-Butyl-4-chloro-1-[(2'-(1H-tetrazol-5-yl)-biphenyl-4-yl)methyl]imidazole- 5-carboxylic acid or a pharmaceutically acceptable salt thereof.

19. Method of claim 4 wherein the compound of formula II is 2-Propyl-4-chloro-1-[(2'-(1H-tetrazol-5-yl)-biphenyl-4-yl)methyl]imidazole -5-carboxylic acid or a pharmaceutically acceptable salt thereof.

20. Method of claim 4 wherein the compound of formula II is 2-Propyl-4-trifluoromethyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]i midazole-5-carboxylic acid or a pharmaceutically acceptable salt thereof.

21. Method of claim 4 wherein the compound of formula II is 2-Propyl-4-trifluoromethyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]- 5-(hydroxylmethyl)imidazole or a pharmaceutically acceptable salt thereof.

22. Method of claim 4 wherein the compound of formula II is 2-Butyl-4-trifluoromethyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]im idazole-5-carboxylic acid or a pharmaceutically acceptable salt thereof.

23. Method of claim 4 wherein the compound of formula II is 2-Propyl-4-trifluoromethyl-1-[(2'-(carboxybiphenyl-4-yl)methyl]imidazole-5 -carboxaldehyde or a pharmaceutically acceptable salt thereof.

24. Method of claim 4 wherein the compound of formula II is 2-Propyl-4-pentafluoroethyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl] -5-(hydroxymethyl)imidazole or a pharmaceutically acceptable salt thereof.

25. Method of claim 4 wherein the compound of formula II is 2-Propyl-4-pentafluoroethyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl] imidazole-5-carboxylic acid or a pharmaceutically acceptable salt thereof.

26. Method of claim 4 wherein the compound of formula II is 2-Propyl-4-pentafluoroethyl-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]im idazole-5-carboxaldehyde or a pharmaceutically acceptable salt thereof.

27. Method of claim 4 wherein the compound of formula II is 1-[(2'-(1H-Tetrazol-5-yl)biphenyl-4-yl)methyl]-4-phenyl-2-propylimidazole- 5-carboxaldehyde or a pharmaceutically acceptable salt thereof.

28. Method of claim 4 wherein the compound of formula II is 1-[(2'-Carboxybiphenyl-4-yl)methyl]-4-phenyl-2-propylimidazole-5-carboxald ehyde or a pharmaceutically acceptable salt thereof.

29. A method of treating chronic renal failure mediated by AII in a mammal comprising administering to the mammal a therapeutically effective amount of a pharmaceutical composition having the formula (I): ##STR69## wherein R.sup.1 is 4--CO.sub.2 H; 4--CO.sub.2 R.sup.9 ; ##STR70## R.sup.2 is H; Cl; Br; I; F; NO.sub.2 ; CN; alkyl of 1 to 4 carbon atoms; acyloxy of 1 to 4 carbon atoms; alkoxy of 1 to 4 carbon atoms; CO.sub.2 H; CO.sub.2 R.sup.9 ; NHSO.sub.2 CH.sub.3 ; NHSO.sub.2 CF.sub.3 ; CONHOR.sup.12 ; SO.sub.2 NH.sub.2 ; ##STR71## aryl; or furyl; R.sup.3 is H; Cl, Br, I or F; alkyl of 1 to 4 carbon atoms or alkoxy of 1 to 4 carbon atoms;

R.sup.4 is CN, NO.sub.2 or CO.sub.2 R.sup.11 ;

R.sup.5 is H, alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms, alkenyl or alkynyl of 2 to 4 carbon atoms;

R.sup.6 is alkyl of 2 to 10 carbon atoms, alkenyl or alkynyl of 3 to 10 carbon atoms or the same groups substituted with F or CO.sub.2 R.sup.14 ; cycloalkyl of 3 to 8 carbon atoms, cycloalkylalkyl of 4 to 10 carbon atoms; cycloalkylalkenyl or cycloalkylalkynyl of 5 to 10 carbon atoms; (CH.sub.2).sub.s Z(CH.sub.2).sub.m R.sup.5 optionally substituted with F or CO.sub.2 R.sup.14 ; benzyl or benzyl substituted on the phenyl ring with 1 or 2 halogens, alkoxy of 1 to 4 carbon atoms, alkyl of 1 to 4 carbon atoms or nitro;

R.sup.7 is H, F, Cl, Br, I, NO.sub.2, C.sub.v F.sub.2v+1, where v=1-6; C.sub.6 F.sub.5 ; CN; ##STR72## straight or branched alkyl of 1 to 6 carbon atoms; phenyl or phenylalkyl, where alkyl is 1 to 3 carbon atoms; or substituted phenyl or substituted phenylalkyl, where alkyl is 1 to 3 carbon atoms, substituted with one or two substituents selected from alkyl of 1 to 4 carbon atoms, F, Cl, Br, OH, OCH.sub.3, CF.sub.3, and COOR, where R is H, alkyl of 1 to 4 carbon atoms, or phenyl;

R.sup.8 is H, CN, alkyl of 1 to 10 carbon atoms, alkenyl of 3 to 10 carbon atoms, or the same groups substituted with F; phenylalkenyl wherein the alkenyl portion is 2 to 6 carbon atoms; --(CH.sub.2).sub.m -imidazol-1-yl; --(CH.sub.2).sub.m -1,2,3-triazolyl optionally substituted with one or two groups selected from CO.sub.2 CH.sub.3 or alkyl of 1 to 4 carbon atoms; --(CH.sub.2).sub.s -tetrazolyl; ##STR73## R.sup.9 is ##STR74## R.sup.10 is alkyl of 1 to 6 carbon atoms or perfluoroalkyl of 1 to 6 carbon atoms, 1-adamantyl, 1-naphthyl, 1-(1-naphthyl)ethyl, or (CH.sub.2).sub.p C.sub.6 H.sub.5 ;

R.sup.11 is H, alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms, phenyl or benzyl;

R.sup.12 is H, methyl or benzyl;

R.sup.13 is --CO.sub.2 H; --CO.sub.2 R.sup.9 ; --CH.sub.2 CO.sub.2 H, --CH.sub.2 CO.sub.2 R.sup.9 ; ##STR75## --PO.sub.3 H.sub.2 ; --C(CF.sub.3).sub.2 OH; --NHSO.sub.2 CH.sub.3 ; --NHSO.sub.2 CF.sub.3 ; --NHCOCF.sub.3 ; --CONHOR.sup.12 ; --SO.sub.2 NH.sub.2 ; ##STR76## R.sup.14 is H, alkyl or perfluoroalkyl of 1 to 8 carbon atoms, cycloalkyl of 3 to 6 carbon atoms, phenyl or benzyl;

R.sup.15 is H, alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms, phenyl, benzyl, acyl of 1 to 4 carbon atoms, phenacyl;

R.sup.16 is H, alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms, (CH.sub.2).sub.p C.sub.6 H.sub.5, OR.sup.17, or NR.sup.18 R.sup.19 ;

R.sup.17 is H, alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms, phenyl or benzyl;

R.sup.18 and R.sup.19 independently are H, alkyl of 1 to 4 carbon atoms, phenyl, benzyl, .alpha.-methylbenzyl, or taken together with the nitrogen form a ring of the formula ##STR77## Q is NR.sup.20, O or CH.sub.2 ; R.sup.20 is H, alkyl of 1-4 carbon atoms, or phenyl;

R.sup.21 is alkyl of 1 to 6 carbon atoms, --NR.sup.22 R.sup.23, or ##STR78## R.sup.22 and R.sup.23 independently are H, alkyl of 1 to 6 carbon atoms, benzyl, or are taken together as (CH.sub.2).sub.u where u is 3-6;

R.sup.24 is H, CH.sub.3 or --C.sub.6 H.sub.5 ;

R.sup.25 is NR.sup.27 R.sup.28, OR.sup.28, NHCONH.sub.2, NHCSNH.sub.2, ##STR79## R.sup.26 is hydrogen, alkyl with from 1 to 6 carbon atoms, benzyl, or allyl;

R.sup.27 and R.sup.28 are independently hydrogen, alkyl with from 1 to 5 carbon atoms, or phenyl;

R.sup.29 and R.sup.30 are independently alkyl of 1-4 carbon atoms or taken together are --(CH.sub.2).sub.q --;

R.sup.31 is H, alkyl of 1 to 4 carbon atoms; --CH.sub.2 CH.dbd.CH.sub.2 or --CH.sub.2 C.sub.6 H.sub.4 R.sup.32 ;

R.sup.32 is H, NO.sub.2, NH.sub.2, OH or OCH.sub.3 ;

X is a carbon-carbon single bond, --CO--, --CH.sub.2 --, --O--, --S--, --NH--, ##STR80## --OCH.sub.2 --, --CH.sub.2 O--, --SCH.sub.2 --, --CH.sub.2 S--, --NHC(R.sup.27)(R.sup.28)--, --NR.sup.23 SO.sub.2 --, --SO.sub.2 NR.sup.23 --, --C(R.sup.27)(R.sup.28)NH--, --CH.dbd.CH--, --CF.dbd.CF--, --CH.dbd.CF--, --CF.dbd.CH--, --CH.sub.2 CH.sub.2 --, --CF.sub.2 CF.sub.2 --, ##STR81## Y is O or S; Z is O, NR.sup.11, or S;

m is 1 to 5;

n is 1 to 10;

p is 0 to 3;

q is 2 to 3;

r is 0 to 2;

s is 0 to 5;

t is 0 or 1;

or a pharmaceutically acceptable salt thereof; provided that:

(1) the R.sup.1 group is not in the ortho position;

(2) when R.sup.1 is ##STR82## X is a single bond, and R.sup.13 is CO.sub.2 H, or ##STR83## then R.sup.13 must be in the ortho or meta position; or when R.sup.1 and X are as above and R.sup.13 is NHSO.sub.2 CF.sub.3 or NHSO.sub.2 CH.sub.3, R.sup.13 must be ortho;

(3) when R.sup.1 is ##STR84## and X is other than a single bond, then R.sup.13 must be ortho except when X=NR.sup.23 CO and R.sup.13 is NHSO.sub.2 CF.sub.3 or NHSO.sub.2 CH.sub.3, then R.sup.13 must be ortho or meta;

(4) when R.sup.1 is 4--CO.sub.2 H or a salt thereof, R.sup.6 cannot be S-alkyl;

(5) when R.sup.1 is 4--CO.sub.2 H or a salt thereof, the substituent on the 4-position of the imidazole cannot be CH.sub.2 OH, CH.sub.2 OCOCH.sub.3, or CH.sub.2 CO.sub.2 H;

(6) when R.sup.1 is ##STR85## X is --OCH.sub.2 --, and R.sup.13 is 2--CO.sub.2 H, and R.sup.7 is H then R.sup.6 is not C.sub.2 H.sub.5 S;

(7) when R.sup.1 is ##STR86## and R.sup.6 is n-hexyl, then R.sup.7 and R.sup.8 are not both hydrogen; (8) when R.sup.1 is ##STR87## R.sup.6 is not methoxybenzyl; (9) the R.sup.6 group is not --CHFCH.sub.2 CH.sub.2 CH.sub.3 or CH.sub.2 OH;

(10) when r=O, R.sup.1 is ##STR88## X is --NH--CO--, R.sup.13 is 2--NHSO.sub.2 CF.sub.3, and R.sup.6 is n-propyl, then R.sup.7 and R.sup.8 are not --CO.sub.2 CH.sub.3 ;

(11) when r=0, R.sup.1 is ##STR89## X is NH--CO--, R.sup.13 is 2--COOH, and R.sup.6 is n-propyl, then R.sup.7 and R.sup.8 are not --CO.sub.2 CH.sub.3 ;

(12) when r=1, R.sup.1 = ##STR90## X is a single bond, R.sup.7 is Cl, and R.sup.8 is --CHO, then R.sup.13 is not 3-(tetrazol-5-yl);

(13) when r=1, R.sup.1 = ##STR91## X is a single bond, R.sup.7 is Cl, and R.sup.8 is --CHO, then R.sup.13 is not 4-(tetrazol-5-yl).

30. A method of treating chronic renal failure mediated by AII in a mammal comprising administering to the mammal a therapeutically effective amount of a pharmaceutical composition having the formula (I): ##STR92## wherein R.sup.1 is 4--CO.sub.2 H; 4--CO.sub.2 R.sup.9 ; ##STR93## -- NHSO.sub.2 CH.sub.3 ; --4--NHSO.sub.2 CF.sub.3 ; --CONHOR.sup.12 ; ##STR94## R.sup.2 is H; Cl; Br; I; F; NO.sub.2 ; alkyl of 1 to 4 carbon atoms; acyloxy of 1 to 4 carbon atoms; alkoxy of 1 to 4 carbon atoms; CO.sub.2 H; CO.sub.2 R.sup.9 ; NHSO.sub.2 CH.sub.3 ; NHSO.sub.2 CF.sub.3 ; CONHOR.sup.12 ; SO.sub.2 NH.sub.2 ; aryl; or furyl; or ##STR95## R.sup.7 is H, F, Cl, Br, I, NO.sub.2, C.sub.v F.sub.2v+1, where v=1-6; C.sub.6 F.sub.5 ; CN;

R.sup.8 is H, CN, alkyl of 1 to 10 carbon atoms, alkenyl of 3 to 10 carbon atoms, or the same groups substituted with F; phenylalkenyl wherein the alkenyl portion is 2 to 6 carbon atoms; --(CH.sub.2).sub.m -imidazol-1-yl; --(CH.sub.2).sub.m -1,2,3-triazolyl optionally substituted with one or two groups selected from CO.sub.2 CH.sub.3 or alkyl of 1 to 4 carbon atoms; --(CH.sub.2).sub.m -tetrazolyl; ##STR96## X is a carbon-carbon single bond, --CO--, --O--, --S--, --NH--, --NR.sup.26 --, --CONR.sup.23 --, --NR.sup.23 CO--, --OCH.sub.2 --, --CH.sub.2 O--, --SCH.sub.2 --, --CH.sub.2 S--, --NHC(R.sup.27)(R.sup.28)--, --NR.sup.23 SO.sub.2 --, SO.sub.2 NR.sup.23 --, C(R.sup.27)(R.sup.28)NH--, --CH.dbd.CH--, --CF.dbd.CF--, --CH.dbd.CF--, --CF.dbd.CH--, --CH.sub.2 CH.sub.2 --, --CF.sub.2 CF.sub.2 --, ##STR97## or pharmaceutically suitable salt thereof.

31. A method of treating chronic renal failure mediated by AII in a mammal comprising administering to the mammal a therapeutically effective amount of a pharmaceutical composition having the formula (I): ##STR98## wherein R.sup.1 is 4--CO.sub.2 H; 4--CO.sub.2 R.sup.9 ; ##STR99## -- NHSO.sub.2 CH.sub.3 ; --4--NHSO.sub.2 CF.sub.3 ; --CONHOR.sup.12 ; ##STR100## R.sup.2 is H; Cl; Br; I; F; NO.sub.2 ; CN; alkyl of 1 to 4 carbon atoms; acyloxy of 1 to 4 carbon atoms; alkoxy of 1 to 4 carbon atoms; CO.sub.2 H; CO.sub.2 R.sup.9 ; NHSO.sub.2 CH.sub.3 ; NHSO.sub.2 CF.sub.3 ; CONHOR.sup.12 ; SO.sub.2 NH.sub.2 ; ##STR101## aryl; or furyl; R.sup.3 is H; Cl, Br, I or F; alkyl of 1 to 4 carbon atoms or alkoxy of 1 to 4 carbon atoms;

R.sup.4 is CN, NO.sub.2 or CO.sub.2 R.sup.11 ;

R.sup.5 is H, alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms, alkenyl or alkynyl of 2 to 4 carbon atoms;

R.sup.6 is alkyl of 2 to 10 carbon atoms, alkenyl or alkynyl of 3 to 10 carbon atoms or the same groups substituted with F or CO.sub.2 R.sup.14 ; cycloalkyl of 3 to 8 carbon atoms, cycloalkylalkyl of 4 to 10 carbon atoms; cycloalkylalkenyl or cycloalkylalkynyl of 5 to 10 carbon atoms; (CH.sub.2).sub.s Z(CH.sub.2).sub.m R.sup.5 optionally substituted with F or CO.sub.2 R.sup.14 ; benzyl or benzyl substituted on the phenyl ring with 1 or 2 halogens, alkoxy of 1 to 4 carbon atoms, alkyl of 1 to 4 carbon atoms or nitro;

R.sup.7 is H, F, Cl, Br, I, NO.sub.2, C.sub.v F.sub.2v+1, where v=1-6; C.sub.6 F.sub.5 ; CN; ##STR102## straight or branched alkyl of 1 to 6 carbon atoms; phenyl or phenylalkyl, where alkyl is 1 to 3 carbon atoms; or substituted phenyl or substituted phenylalkyl, where alkyl is 1 to 3 carbon atoms, substituted with one or two substituents selected from alkyl of 1 to 4 carbon atoms, F, Cl, Br, OH, OCH.sub.3, CF.sub.3, and COOR, where R is H, alkyl of 1 to 4 carbon atoms, or phenyl;

R.sup.8 is ##STR103## R.sup.9 is ##STR104## R.sup.10 is alkyl of 1 to 6 carbon atoms or perfluoroalkyl of 1 to 6 carbon atoms, 1-adamantyl, 1-naphthyl, 1-(1-naphthyl)ethyl, or (CH.sub.2).sub.p C.sub.6 H.sub.5 ;

R.sup.11 is H, alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms, phenyl or benzyl;

R.sup.12 is H, methyl or benzyl;

R.sup.13 is --CO.sub.2 H; --CO.sub.2 R.sup.9 ; --CH.sub.2 CO.sub.2 H, --CH.sub.2 CO.sub.2 R.sup.9 ; ##STR105## --PO.sub.3 H.sub.2 ; --C(CF.sub.3).sub.2 OH; --NHSO.sub.2 CH.sub.3 ; --NHSO.sub.2 CF.sub.3 ; --NHCOCF.sub.3 ; --CONHOR.sup.12 ; --SO.sub.2 NH.sub.2 ; ##STR106## R.sup.14 is H, alkyl or perfluoroalkyl of 1 to 8 carbon atoms, cycloalkyl of 3 to 6 carbon atoms, phenyl, or benzyl;

R.sup.15 is H, alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms, phenyl, benzyl, acyl of 1 to 4 carbon atoms, phenacyl;

R.sup.16 is H, alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms, (CH.sub.2).sub.p C.sub.6 H.sub.5, OR.sup.17, or NR.sup.18 R.sup.19 ;

R.sup.17 is H, alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms, phenyl or benzyl;

R.sup.18 and R.sup.19 independently are H, alkyl of 1 to 4 carbon atoms, phenyl, benzyl, .alpha.-methylbenzyl, or taken together with the nitrogen form a ring of the formula ##STR107## Q is NR.sup.20, O or CH.sub.2 ; R.sup.20 is H, alkyl of 1-4 carbon atoms, or phenyl;

R.sup.21 is alkyl of 1 to 6 carbon atoms, --NR.sup.22 R.sup.23, or ##STR108## R.sup.22 and R.sup.23 independently are H, alkyl of 1 to 6 carbon atoms, benzyl, or are taken together as (CH.sub.2).sub.u where u is 3-6;

R.sup.24 is H, CH.sub.3 or --C.sub.6 H.sub.5 ;

R.sup.25 is NR.sup.27 R.sup.28, OR.sup.28, NHCONH.sub.2, NHCSNH.sub.2, ##STR109## R.sup.26 is hydrogen, alkyl with from 1 to 6 carbon atoms, benzyl, or allyl;

R.sup.27 and R.sup.28 are independently hydrogen, alkyl with from 1 to 5 carbon atoms, or phenyl;

R.sup.29 and R.sup.30 are independently alkyl of 1-4 carbon atoms or taken together are --(CH.sub.2).sub.q --;

R.sup.31 is H, alkyl of 1 to 4 carbon atoms, --CH.sub.2 CH.dbd.CH.sub.2 or --CH.sub.2 C.sub.6 H.sub.r R.sup.32 ;

R.sup.32 is H, NO.sub.2, NH.sub.2, OH or OCH.sub.3 ;

X is a carbon-carbon single bond, --CO--, --CH.sub.2 --, --O--, --S--, --NH--, ##STR110## --OCH.sub.2 --, --CH.sub.2 O--, --SCH.sub.2 --, --CH.sub.2 S--, --NHC(R.sup.27)(R.sup.28)--, --NR.sup.23 SO.sub.2 --, --SO.sub.2 NR.sup.23 --, --C(R.sup.27)(R.sup.28)NH--, --CH.dbd.CH--, --CF.dbd.CF--, --CH.dbd.CF--, --CF.dbd.CH--, --CH.sub.2 CH.sub.2 --, --CF.sub.2 CF.sub.2 --, ##STR111## Y is O or S; Z is O, NR.sup.11, or S;

m is 1 to 5;

n is 1 to 10;

p is 0 to 3;

q is 2 to 3;

r is 0 to 2;

s is 0 to 5;

t is 0 or 1;

or a pharmaceutically acceptable salt thereof; provided that:

(1) the R.sup.1 group is not in the ortho position;

(2) when R.sup.1 is ##STR112## X is a single bond, and R.sup.13 is CO.sub.2 H, or ##STR113## then R.sup.13 must be in the ortho or meta position; or when R.sup.1 and X are as above and R.sup.13 is NHSO.sub.2 CF.sub.3 or NHSO.sub.2 CH.sub.3, R.sup.13 must be ortho;

(3) when R.sup.1 is ##STR114## and X is other than a single bond, then R.sup.13 must be ortho except when X=NR.sup.23 CO and R.sup.13 is NHSO.sub.2 CF.sub.3 or NHSO.sub.2 CH.sub.3, then R.sup.13 must be ortho or meta;

(4) when R.sup.1 is 4--CO.sub.2 H or a salt thereof, R.sup.6 cannot be S-alkyl;

(5) when R.sup.1 is 4--CO.sub.2 H or a salt thereof, the substituent on the 4-position of the imidazole cannot be CH.sub.2 OH, CH.sub.2 OCOCH.sub.3, or CH.sub.2 CO.sub.2 H;

(6) when R.sup.1 is ##STR115## R.sup.6 is not methoxybenzyl; (7) the R.sup.6 group is not ##STR116## or CH.sub.2 OH.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.